Two germline mutations in OATP1B1, c.388A>G (p.Asn130Asp) and c.521T>C (p.Val174Ala), have been associated with side effects after treatment of HCC patients with sorafenib. Here, SLCO1B1 is linked to hepatocellular carcinoma.